Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma

Chia Hui Lo, Chia Ming Chang, Shih Wen Tang, Wen Yu Pan, Cheng Chieh Fang, Yin Chen, Ping Yi Wu, Kai Yun Chen, Hsin I. Ma, Xiao Xiao, Mi Hua Tao

研究成果: 雜誌貢獻文章

18 引文 (Scopus)

摘要

Background: Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat. The interleukin (IL)-12 family cytokines, including IL-12, IL-23 and IL-27, display overlapping, but not redundant, roles in regulating lymphocyte subpopulations. IL-12 is known as a potent antitumor cytokine, whereas the results of the antitumor effect of IL-23 and IL-27 are inconsistent. The present study aimed to directly compare the relative antitumor efficacy of these three IL-12 family cytokines on HCC. Methods: A murine orthotopic BNL HCC model, in which the tumor is located in an environment heavily populated with different lymphocyte subsets, was established. The hepatotropic adeno-associated virus serotype 8 (AAV8) vector was used to deliver the cytokine genes aiming to achieve sustained cytokine expression in the liver. Results: AAV8/IL-12 treatment significantly reduced hepatic metastases and prolonged survival time, whereas treatment with AAV8/IL-23 or AAV8/IL-27 had only moderate antitumor effects at a high dose. The antitumor efficacy of these cytokines was positively correlated with their ability to regulate hepatic T cells, natural killer cells and natural killer T cells, with IL-12 greatly increasing the number and activation status of these cells, whereas IL-27 had no effect and IL-23 had a negative effect. AAV8/IL-12 treatment also resulted in a marked decrease in tumor vessel density, which was not observed with AAV8/IL-23 and AAV8/IL-27 treatment. Conclusions: The data obtained in the present study highlight the importance of local lymphocytes and anti-angiogenesis for influencing the antitumor activity of these three IL-12 family cytokines and suggest that IL-12 is the best candidate for treating HCC.
原文英語
頁(從 - 到)423-434
頁數12
期刊Journal of Gene Medicine
12
發行號5
DOIs
出版狀態已發佈 - 五月 2010
對外發佈Yes

指紋

Interleukin-12
Dependovirus
Hepatocellular Carcinoma
Interleukin-27
Interleukin-23
Cytokines
Lymphocyte Subsets
Neoplasms
Natural Killer T-Cells
Liver
Serogroup
Natural Killer Cells
Hepatocytes
Lymphocytes
Neoplasm Metastasis
T-Lymphocytes

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

引用此文

Lo, C. H., Chang, C. M., Tang, S. W., Pan, W. Y., Fang, C. C., Chen, Y., ... Tao, M. H. (2010). Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. Journal of Gene Medicine, 12(5), 423-434. https://doi.org/10.1002/jgm.1452

Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. / Lo, Chia Hui; Chang, Chia Ming; Tang, Shih Wen; Pan, Wen Yu; Fang, Cheng Chieh; Chen, Yin; Wu, Ping Yi; Chen, Kai Yun; Ma, Hsin I.; Xiao, Xiao; Tao, Mi Hua.

於: Journal of Gene Medicine, 卷 12, 編號 5, 05.2010, p. 423-434.

研究成果: 雜誌貢獻文章

Lo, CH, Chang, CM, Tang, SW, Pan, WY, Fang, CC, Chen, Y, Wu, PY, Chen, KY, Ma, HI, Xiao, X & Tao, MH 2010, 'Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma', Journal of Gene Medicine, 卷 12, 編號 5, 頁 423-434. https://doi.org/10.1002/jgm.1452
Lo, Chia Hui ; Chang, Chia Ming ; Tang, Shih Wen ; Pan, Wen Yu ; Fang, Cheng Chieh ; Chen, Yin ; Wu, Ping Yi ; Chen, Kai Yun ; Ma, Hsin I. ; Xiao, Xiao ; Tao, Mi Hua. / Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. 於: Journal of Gene Medicine. 2010 ; 卷 12, 編號 5. 頁 423-434.
@article{4c7191a2d1aa48c996bc90ff669f3241,
title = "Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma",
abstract = "Background: Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat. The interleukin (IL)-12 family cytokines, including IL-12, IL-23 and IL-27, display overlapping, but not redundant, roles in regulating lymphocyte subpopulations. IL-12 is known as a potent antitumor cytokine, whereas the results of the antitumor effect of IL-23 and IL-27 are inconsistent. The present study aimed to directly compare the relative antitumor efficacy of these three IL-12 family cytokines on HCC. Methods: A murine orthotopic BNL HCC model, in which the tumor is located in an environment heavily populated with different lymphocyte subsets, was established. The hepatotropic adeno-associated virus serotype 8 (AAV8) vector was used to deliver the cytokine genes aiming to achieve sustained cytokine expression in the liver. Results: AAV8/IL-12 treatment significantly reduced hepatic metastases and prolonged survival time, whereas treatment with AAV8/IL-23 or AAV8/IL-27 had only moderate antitumor effects at a high dose. The antitumor efficacy of these cytokines was positively correlated with their ability to regulate hepatic T cells, natural killer cells and natural killer T cells, with IL-12 greatly increasing the number and activation status of these cells, whereas IL-27 had no effect and IL-23 had a negative effect. AAV8/IL-12 treatment also resulted in a marked decrease in tumor vessel density, which was not observed with AAV8/IL-23 and AAV8/IL-27 treatment. Conclusions: The data obtained in the present study highlight the importance of local lymphocytes and anti-angiogenesis for influencing the antitumor activity of these three IL-12 family cytokines and suggest that IL-12 is the best candidate for treating HCC.",
keywords = "Adeno-associated virus, Hepatocellular carcinoma, IL-12, IL-23, IL-27",
author = "Lo, {Chia Hui} and Chang, {Chia Ming} and Tang, {Shih Wen} and Pan, {Wen Yu} and Fang, {Cheng Chieh} and Yin Chen and Wu, {Ping Yi} and Chen, {Kai Yun} and Ma, {Hsin I.} and Xiao Xiao and Tao, {Mi Hua}",
year = "2010",
month = "5",
doi = "10.1002/jgm.1452",
language = "English",
volume = "12",
pages = "423--434",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma

AU - Lo, Chia Hui

AU - Chang, Chia Ming

AU - Tang, Shih Wen

AU - Pan, Wen Yu

AU - Fang, Cheng Chieh

AU - Chen, Yin

AU - Wu, Ping Yi

AU - Chen, Kai Yun

AU - Ma, Hsin I.

AU - Xiao, Xiao

AU - Tao, Mi Hua

PY - 2010/5

Y1 - 2010/5

N2 - Background: Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat. The interleukin (IL)-12 family cytokines, including IL-12, IL-23 and IL-27, display overlapping, but not redundant, roles in regulating lymphocyte subpopulations. IL-12 is known as a potent antitumor cytokine, whereas the results of the antitumor effect of IL-23 and IL-27 are inconsistent. The present study aimed to directly compare the relative antitumor efficacy of these three IL-12 family cytokines on HCC. Methods: A murine orthotopic BNL HCC model, in which the tumor is located in an environment heavily populated with different lymphocyte subsets, was established. The hepatotropic adeno-associated virus serotype 8 (AAV8) vector was used to deliver the cytokine genes aiming to achieve sustained cytokine expression in the liver. Results: AAV8/IL-12 treatment significantly reduced hepatic metastases and prolonged survival time, whereas treatment with AAV8/IL-23 or AAV8/IL-27 had only moderate antitumor effects at a high dose. The antitumor efficacy of these cytokines was positively correlated with their ability to regulate hepatic T cells, natural killer cells and natural killer T cells, with IL-12 greatly increasing the number and activation status of these cells, whereas IL-27 had no effect and IL-23 had a negative effect. AAV8/IL-12 treatment also resulted in a marked decrease in tumor vessel density, which was not observed with AAV8/IL-23 and AAV8/IL-27 treatment. Conclusions: The data obtained in the present study highlight the importance of local lymphocytes and anti-angiogenesis for influencing the antitumor activity of these three IL-12 family cytokines and suggest that IL-12 is the best candidate for treating HCC.

AB - Background: Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat. The interleukin (IL)-12 family cytokines, including IL-12, IL-23 and IL-27, display overlapping, but not redundant, roles in regulating lymphocyte subpopulations. IL-12 is known as a potent antitumor cytokine, whereas the results of the antitumor effect of IL-23 and IL-27 are inconsistent. The present study aimed to directly compare the relative antitumor efficacy of these three IL-12 family cytokines on HCC. Methods: A murine orthotopic BNL HCC model, in which the tumor is located in an environment heavily populated with different lymphocyte subsets, was established. The hepatotropic adeno-associated virus serotype 8 (AAV8) vector was used to deliver the cytokine genes aiming to achieve sustained cytokine expression in the liver. Results: AAV8/IL-12 treatment significantly reduced hepatic metastases and prolonged survival time, whereas treatment with AAV8/IL-23 or AAV8/IL-27 had only moderate antitumor effects at a high dose. The antitumor efficacy of these cytokines was positively correlated with their ability to regulate hepatic T cells, natural killer cells and natural killer T cells, with IL-12 greatly increasing the number and activation status of these cells, whereas IL-27 had no effect and IL-23 had a negative effect. AAV8/IL-12 treatment also resulted in a marked decrease in tumor vessel density, which was not observed with AAV8/IL-23 and AAV8/IL-27 treatment. Conclusions: The data obtained in the present study highlight the importance of local lymphocytes and anti-angiogenesis for influencing the antitumor activity of these three IL-12 family cytokines and suggest that IL-12 is the best candidate for treating HCC.

KW - Adeno-associated virus

KW - Hepatocellular carcinoma

KW - IL-12

KW - IL-23

KW - IL-27

UR - http://www.scopus.com/inward/record.url?scp=77952575808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952575808&partnerID=8YFLogxK

U2 - 10.1002/jgm.1452

DO - 10.1002/jgm.1452

M3 - Article

C2 - 20440753

AN - SCOPUS:77952575808

VL - 12

SP - 423

EP - 434

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 5

ER -